Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ocular Therapeutix (OCUL)
NASDAQ:OCUL
RESEARCH TOOLSreports
OCUL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.06 - $11.78
Previous CloseN/A
Volume219.73K
Average Volume (3M)955.01K
Market Cap
$1.13B
Enterprise Value$1.10B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Mar 06, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding157,217,420
10 Day Avg. Volume993,539
30 Day Avg. Volume955,008
Standard Deviation0.27
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)18.42
Price to Cash Flow (P/CF)-7.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit20.71
Enterprise Value/Ebitda-7.06
Forecast
1Y Price Target
$18.13Price Target Upside150.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Ocular Therapeutix News
PremiumCompany Announcements
Ocular Therapeutix Approves New CEO Compensation Package
PremiumCompany Announcements
Ocular Therapeutix Reports Q3 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsOcular is making significant strides in the pivotal SOL-1 trial for Axpaxli in wet AMD, reflecting strong progress in clinical development.
Financial PositionA strong cash position with $427.2M in cash provides financial stability and resources to support ongoing and future initiatives.
Market PotentialThe potential to expand Axpaxli to additional retinal indications is seen as a positive development, indicating opportunities for market growth.
Bears Say
Clinical RisksRisks include, but are not limited to, the potential failure of OTX-TKI or OTX-TIC in clinical trials, which could impact future prospects.
Dilution RiskPotential dilution risk could affect shareholder value, posing a concern for investors.
Revenue PerformanceTotal revenue was $15.4M, representing 2.3% YoY growth yet missing the analyst's projection of $16.8M, highlighting a shortfall in expected financial performance.
---
Ownership Overview
8.84% Insiders
9.75% Mutual Funds
49.32% Other Institutional Investors
20.74% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OCUL FAQ
What was Ocular Therapeutix’s price range in the past 12 months?
Ocular Therapeutix lowest stock price was $4.06 and its highest was $11.78 in the past 12 months.
What is Ocular Therapeutix’s market cap?
Ocular Therapeutix’s market cap is $1.13B.
When is Ocular Therapeutix’s upcoming earnings report date?
Ocular Therapeutix’s upcoming earnings report date is Mar 06, 2025 which is in 12 days.
How were Ocular Therapeutix’s earnings last quarter?
Ocular Therapeutix released its earnings results on Nov 14, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.243 by $0.023.
Is Ocular Therapeutix overvalued?
According to Wall Street analysts Ocular Therapeutix’s price is currently Undervalued.
Does Ocular Therapeutix pay dividends?
Ocular Therapeutix does not currently pay dividends.
What is Ocular Therapeutix’s EPS estimate?
Ocular Therapeutix’s EPS estimate is -0.25.
How many shares outstanding does Ocular Therapeutix have?
Ocular Therapeutix has 157,217,420 shares outstanding.
What happened to Ocular Therapeutix’s price movement after its last earnings report?
Ocular Therapeutix reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.243. Following the earnings report the stock price went down -6.415%.
Which hedge fund is a major shareholder of Ocular Therapeutix?
Currently, no hedge funds are holding shares in OCUL
---
Ocular Therapeutix Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.13 (150.07% Upside)
$18.13 (150.07% Upside)
Blogger Sentiment
Bullish
OCUL Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 105.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $342.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.63%
12-Months-Change
Fundamentals
Return on Equity
-96.89%
Trailing 12-Months
Asset Growth
201.98%
Trailing 12-Months
Company Description
Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
---
OCUL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, highlighting significant progress in clinical trial enrollment, strong demand for AXPAXLI, and a solid financial position. The only notable concern was the need for both SOL-1 and SOL-R data for regulatory submission, which may impact timelines. Overall, the outlook is promising, especially with the continued success of DEXTENZA and the anticipation of strong results from the AXPAXLI trials.Read More>---
OCUL Stock 12 Month Forecast
Average Price Target
$18.13
▲(150.07% Upside)
Technical Analysis
Best Analysts Covering OCUL
1 Year
1 Year Success Rate
19/41 ratings generated profit
1 Year Average Return
+14.31%
reiterated a buy rating 7 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 46.34% of your transactions generating a profit, with an average return of +14.31% per trade.
---